Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1990 1
1992 2
1993 2
1995 1
1996 2
1997 5
1999 1
2000 1
2001 2
2002 5
2003 2
2004 4
2005 6
2006 8
2007 3
2008 7
2009 12
2010 9
2011 11
2012 17
2013 15
2014 9
2015 12
2016 25
2017 28
2018 25
2019 27
2020 28
2021 52
2022 40
2023 35
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

360 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following terms were ignored: %, %, %, %
The following terms were not found in PubMed: 22Ribonuclease, 5Bnm
Page 1
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Monk BJ, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Hurtado de Mendoza MO, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Martin Nguyen A, Monberg MJ, Colombo N, Lorusso D. Monk BJ, et al. Lancet Oncol. 2023 Apr;24(4):392-402. doi: 10.1016/S1470-2045(23)00052-9. Epub 2023 Mar 3. Lancet Oncol. 2023. PMID: 36878237 Clinical Trial.
PRO instruments were the EORTC Quality-of-Life-Core 30 (QLQ-C30), the EORTC cervical cancer module (QLQ-CX24), and the EuroQol-5 dimension-5 level (EQ-5D-5L) visual analogue scale, each collected before treatment at cycles 1-14 and every other cycle thereafter. ...FINDINGS …
PRO instruments were the EORTC Quality-of-Life-Core 30 (QLQ-C30), the EORTC cervical cancer module (QLQ-CX24), and the EuroQol-5 dimension-5 …
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L, Wang J, Pan JJ, Saretsky TL, Perini RF, He CS, Mody K, Cella D. Motzer R, et al. Lancet Oncol. 2022 Jun;23(6):768-780. doi: 10.1016/S1470-2045(22)00212-1. Epub 2022 Apr 27. Lancet Oncol. 2022. PMID: 35489363 Free PMC article. Clinical Trial.
Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease-Related Symptoms (FKSI-DRS), European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), and the EQ-5D-3 Level (EQ-5D-3L) preference questi …
Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease-Related Symptoms (FKSI-DRS), European Organisation for the Research and …
Lanthanide Photocatalysis.
Qiao Y, Schelter EJ. Qiao Y, et al. Acc Chem Res. 2018 Nov 20;51(11):2926-2936. doi: 10.1021/acs.accounts.8b00336. Epub 2018 Oct 18. Acc Chem Res. 2018. PMID: 30335356
To control and predict the photocatalytic reactivities, we have also performed photophysical and photochemical studies on a series of mixed-ligand Ce(III) guanidinate-amide and guanidinate-aryloxide complexes to establish structure-property relationship for Ce(III) …
To control and predict the photocatalytic reactivities, we have also performed photophysical and photochemical studies on a series of mixed- …
Vacuum-deposited Rb3CeI6 for deep-blue-light-emitting diodes.
Du H, Yang L, Pang J, Shen Z, Li J, Dong X, Luo Y, Luo J, Tang J. Du H, et al. Opt Lett. 2023 Jun 1;48(11):2777-2780. doi: 10.1364/OL.486168. Opt Lett. 2023. PMID: 37262208
Herein, we vacuum thermally deposited a film of the lead-free rare earth halide Rb(3)CeI(6), which shows deep blue emission with peaks at 427 nm and 468 nm. Due to the parity-allowed 5d-4f transition of Ce(III), the excited-state lifetime is as short as 22.3 …
Herein, we vacuum thermally deposited a film of the lead-free rare earth halide Rb(3)CeI(6), which shows deep blue emission with peaks at 42 …
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T, Amonkar M, Norquist JM, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Sevilla I, De La Fouchardiere C, Rivera F, Elez E, Diaz LA Jr, Yoshino T, Van Cutsem E, Yang P, Farooqui M, Le DT. Andre T, et al. Lancet Oncol. 2021 May;22(5):665-677. doi: 10.1016/S1470-2045(21)00064-4. Epub 2021 Apr 1. Lancet Oncol. 2021. PMID: 33812497 Clinical Trial.
HRQOL outcomes were mean change from baseline to prespecified week 18 in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and EORTC Quality of Life Questionnaire-Colorectal 29 (EORTC QLQ-CR29) scale and item scores, …
HRQOL outcomes were mean change from baseline to prespecified week 18 in European Organisation for Research and Treatment of Cancer Quality …
Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy.
Georgieva D, Langley J, Hartkopf K, Hawk L, Margolis A, Struck A, Felton E, Hsu D, Gidal BE. Georgieva D, et al. Epilepsy Behav. 2023 Apr;141:109159. doi: 10.1016/j.yebeh.2023.109159. Epub 2023 Mar 7. Epilepsy Behav. 2023. PMID: 36893722 Clinical Trial.
OBJECTIVE: Epidiolex (CBD) is FDA-approved for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis complex (TSC). Phase III studies suggest that certain adverse effects (AEs), possibly linked to pharmacokinetic/pharmacodynam …
OBJECTIVE: Epidiolex (CBD) is FDA-approved for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sc …
Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).
Jamieson C, Canuso CM, Ionescu DF, Lane R, Qiu X, Rozjabek H, Molero P, Fu DJ. Jamieson C, et al. Qual Life Res. 2023 Nov;32(11):3053-3061. doi: 10.1007/s11136-023-03451-9. Epub 2023 Jul 13. Qual Life Res. 2023. PMID: 37439961 Free PMC article.
Outcome assessments included: Beck Hopelessness Scale (BHS), Quality of Life (QoL) in Depression Scale (QLDS), European QoL Group-5-Dimension-5-Level (EQ-5D-5L), and 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9). ...Relative risk (95% CI) of reporting …
Outcome assessments included: Beck Hopelessness Scale (BHS), Quality of Life (QoL) in Depression Scale (QLDS), European QoL Group-5-Dimensio …
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
Reck M, Schenker M, Lee KH, Provencio M, Nishio M, Lesniewski-Kmak K, Sangha R, Ahmed S, Raimbourg J, Feeney K, Corre R, Franke FA, Richardet E, Penrod JR, Yuan Y, Nathan FE, Bhagavatheeswaran P, DeRosa M, Taylor F, Lawrance R, Brahmer J. Reck M, et al. Eur J Cancer. 2019 Jul;116:137-147. doi: 10.1016/j.ejca.2019.05.008. Epub 2019 Jun 11. Eur J Cancer. 2019. PMID: 31195357 Free article. Clinical Trial.
During treatment, mean changes from baseline with nivolumab + ipilimumab showed early, clinically meaningful improvements in LCSS ASBI/3-IGI and EQ-5D VAS/UI; with chemotherapy, symptoms and health-related quality of life remained stable (LCSS ASBI/3-IGI, EQ-5D UI) …
During treatment, mean changes from baseline with nivolumab + ipilimumab showed early, clinically meaningful improvements in LCSS ASBI/3-IGI …
Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
Bergman M, Tundia N, Martin N, Suboticki JL, Patel J, Goldschmidt D, Song Y, Wright GC. Bergman M, et al. Arthritis Res Ther. 2022 Jun 24;24(1):155. doi: 10.1186/s13075-022-02813-x. Arthritis Res Ther. 2022. PMID: 35751108 Free PMC article. Clinical Trial.
PROs evaluated included Patient Global Assessment of Disease Activity (PtGA) by visual analog scale (VAS), patient's assessment of pain by VAS, Health Assessment Questionnaire Disability Index (HAQ-DI), morning stiffness duration and severity, 36-Item Short Form Health Survey (SF …
PROs evaluated included Patient Global Assessment of Disease Activity (PtGA) by visual analog scale (VAS), patient's assessment of pain by V …
Thermally Stable Terbium(II) and Dysprosium(II) Bis-amidinate Complexes.
Jin PB, Luo QC, Gransbury GK, Vitorica-Yrezabal IJ, Hajdu T, Strashnov I, McInnes EJL, Winpenny REP, Chilton NF, Mills DP, Zheng YZ. Jin PB, et al. J Am Chem Soc. 2023 Dec 27;145(51):27993-28009. doi: 10.1021/jacs.3c07978. Epub 2023 Nov 24. J Am Chem Soc. 2023. PMID: 37997752 Free PMC article.
The thermostable four-coordinate divalent lanthanide (Ln) bis-amidinate complexes [Ln(Piso)(2)] (Ln = Tb, Dy; Piso = {(NDipp)(2)C(t)Bu}, Dipp = C(6)H(3)(i)Pr(2)-2,6) were prepared by the reduction of parent five-coordinate Ln(III) precursors [Ln(Piso)(2)I] (Ln = Tb, Dy) wi …
The thermostable four-coordinate divalent lanthanide (Ln) bis-amidinate complexes [Ln(Piso)(2)] (Ln = Tb, Dy; Piso = {(NDipp)(2)C(t)Bu}, Dip …
360 results